Boston, MA -- (SBWIRE) -- 05/18/2017 -- Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.

Technavio's analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Get More Details on this Report and a Full Table of Contents at Global Gastroparesis Drugs Market 2017-2021

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-Cadila Pharmaceuticals
-GlaxoSmithKline
-Johnson & Johnson
-Valeant

Other prominent vendors

-Evoke Pharma
-Teva Pharmaceutical Industries
-Theravance Biopharma

Market driver

-Rising cases of diabetes fueling the prevalence of diabetic gastroparesis.
-For a full, detailed list, view our report

Market challenge

-Difficulty in diagnosis is hampering the medication process.
-For a full, detailed list, view our report

Market trend

-Introduction of novel ways for the treatment of gastroparesis symptoms.
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Cadila Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Valeant, Evoke Pharma, Teva Pharmaceutical Industries, Theravance Biopharma

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Gastroparesis Global Clinical Trials Review, H2, 2016
-Diabetic Gastroparesis Global Clinical Trials Review, H1, 2016
-Global Solid Tumors Drugs Market 2016-2020
-Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance
-The Future of Generic Drugs and Strategies for Commercial Success